Bio-Techne Beats Q4 Revenue Forecasts Amid Flat Year-Over-Year Sales
Life sciences tools provider Bio-Techne (NASDAQ:TECH) reported fourth-quarter results that surpassed Wall Street's revenue expectations, though sales remained unchanged from the prior year. Adjusted earnings per share also came in ahead of consensus estimates.